Alvin Shih, Imbria Pharmaceuticals CEO
April 10, 2025 07:00 AM EDTUpdated 09:17 AM
Financing
Startups

Ex­clu­sive: Car­diometa­bol­ic biotech gets $57.5M Se­ries B, with help from Cy­to­ki­net­ics

Kyle LaHucik

Senior Reporter

A biotech in­cu­bat­ed by RA Cap­i­tal has se­cured a $57.5 mil­lion Se­ries B to be­gin a mid-stage tri­al for its car­dio drug this quar­ter and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

A service from the Financial Times